Clinical Trial: A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)

U.S., Sept. 11 -- ClinicalTrials.gov registry received information related to the study (NCT07811869) titled 'A Study to Evaluate Efficacy, Safety, and Tolerability of Remibrutinib in Adult Participants With Severe Chronic Pruritus of Unknown Origin (CPUO)' on Sept. 04.

Brief Summary: The purpose of this phase 3 study is to establish the efficacy, safety and tolerability of remibrutinib in adult participants with severe chronic pruritus of unknown origin (CPUO).

Study Start Date: Oct. 06

Study Type: INTERVENTIONAL

Condition: Chronic Pruritus of Unknown Origin

Intervention: DRUG: Remibrutinib

Oral administration of remibrutinib

DRUG: Placebo

Oral administration of matching placebo.

Recruitment Status: RECRUITING

Sponsor: Novartis...